Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 2;17(2):e0011066.
doi: 10.1371/journal.pntd.0011066. eCollection 2023 Feb.

Primary or secondary prevention of HIV-associated histoplasmosis during the early antiretrovirals for all era

Mathieu Nacher  1   2 , Paul Le Turnier  3 , Philippe Abboud  3 , Ugo Françoise  1 , Aude Lucarelli  4 , Magalie Demar  5   6 , Félix Djossou  3 , Loïc Epelboin  3 , Pierre Couppié  2   7 , Antoine Adenis  1   2
Affiliations

Primary or secondary prevention of HIV-associated histoplasmosis during the early antiretrovirals for all era

Mathieu Nacher et al. PLoS Negl Trop Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Atkinson A, Zwahlen M, Barger D, d’Arminio Monforte A, De Wit S, Ghosn J, et al.. Withholding primary PcP prophylaxis in virologically suppressed HIV patients: an emulation of a pragmatic trial in COHERE. Clin Infect Dis. 2020. - PMC - PubMed
    1. Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, et al.. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis. 2010;51:611–9. 10.1086/655761 - DOI - PubMed
    1. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, et al.. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807–25. https://doi.org/CID51625 [pii] doi: 10.1086/521259 - DOI - PubMed
    1. McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, et al.. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999;28:1049–1056. 10.1086/514744. - DOI - PubMed
    1. Goldman M, Cloud GA, Smedema M, LeMonte A, Connolly P, McKinsey DS, et al.. Does Long-Term Itraconazole Prophylaxis Result in In Vitro Azole Resistance in Mucosal Candida albicans Isolates from Persons with Advanced Human Immunodeficiency Virus Infection? Antimicrob Agents Chemother. 2000;44:1585–1587. - PMC - PubMed

MeSH terms

Substances